Similarly, mice inoculated with PDA cells and treated with Gal-9 mAbs showed significant tumor regression via disruption of the Gal-9–dectin1-dependent immunotolerant environment [139]. This evidence concerns the gene LGALS9 and Patent ductus arteriosus.